Mannkind: Pay

Mannkind paid its 3 named executives $9.2M in total in FY2024 (Dec).

Pay$100 in the stock at the end of FY20 → $168
CEO pay is from each proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Pay of each named executive

Michael E. CastagnaChief Executive Officer
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
2 years
Christopher B. PrentissChief Financial Officer
FY2024 (Dec)
1 year
Stuart A. TrossEVP, Human Resources
FY2024 (Dec)Not disclosed
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
3 years
David B. ThomsonEVP, General Counsel and Secretary
FY2022 (Dec)Not disclosed
FY2021 (Dec)Not disclosed
2 years

CEO pay against the pay peers

In FY2025 (Dec), the median CEO pay of the 5 peers with pay on file was $10.4M. CEO pay of Mannkind for that year is not on file.

  1. 1INSMED
  2. 2Krystal Biotech
  3. 3Mirum Pharmaceuticals
  4. 4Adma Biologics
  5. 5Travere Therapeutics
  6. 6MannkindNot disclosed
  7. 7Anika Therapeutics, Inc.Not disclosed
  8. 8Biocryst PharmaceuticalsNot disclosed
  9. 9Dynavax Technologies CorporationNot disclosed
  10. 10Ironwood Pharmaceuticals, Inc.Not disclosed
  11. 11Karyopharm Therapeutics Inc.Not disclosed
  12. 12MacroGenics Inc.Not disclosed
  13. 13Rigel Pharmaceuticals Inc.Not disclosed
  14. 14Vanda Pharmaceuticals Inc.Not disclosed

Pay of each named executive comes from the Summary Compensation Table of each proxy statement. Realized pay adds the value of options used and stock that vested. CEO pay of each peer comes from its own Pay versus Performance table.